XOMA Announces Servier Has Initiated a Proof-of-Concept Gevokizumab Study in Patients With a History of Acute Coronary Syndrome Nov 29, 2012 8:00am EST
XOMA Announces Perindopril and Amlodipine Fixed-Dose Combination Meets Primary Endpoint in Phase 3 PATH Trial Nov 20, 2012 4:05pm EST
XOMA Initiates Safety and Efficacy Study of Gevokizumab in Patients With Non-Infectious Uveitis Currently Controlled by Systemic Treatment Oct 03, 2012 4:00pm EDT
XOMA Announces Servier Has Initiated Phase 3 Gevokizumab Trial in Patients With Behcet's Uveitis Sep 27, 2012 1:12pm EDT
XOMA Receives Orphan Drug Designation From U.S. Food & Drug Administration for Gevokizumab Aug 22, 2012 4:52pm EDT
XOMA to Present at the 2012 Wedbush PacGrow Life Sciences Management Access Conference Aug 08, 2012 5:19pm EDT
XOMA Reports Financial Results for Second Quarter 2012 and Highlights Recent Achievements Aug 07, 2012 4:05pm EDT
XOMA Announces Manufacturing Agreement With Les Laboratoires Servier and Boehringer Ingelheim Aug 03, 2012 8:00am EDT
XOMA to Announce Second Quarter 2012 Financial Results and Host Webcast on August 7 Jul 24, 2012 4:05pm EDT
